MX9700560A - Metodo de uso de integrasa retroviral negativa transdominante en el tratamiento de infecciones retrovirales. - Google Patents
Metodo de uso de integrasa retroviral negativa transdominante en el tratamiento de infecciones retrovirales.Info
- Publication number
- MX9700560A MX9700560A MX9700560A MX9700560A MX9700560A MX 9700560 A MX9700560 A MX 9700560A MX 9700560 A MX9700560 A MX 9700560A MX 9700560 A MX9700560 A MX 9700560A MX 9700560 A MX9700560 A MX 9700560A
- Authority
- MX
- Mexico
- Prior art keywords
- retroviral
- transdominant negative
- hiv
- treatment
- integrase gene
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 108010061833 Integrases Proteins 0.000 title abstract 5
- 206010038997 Retroviral infections Diseases 0.000 title abstract 4
- 102100034343 Integrase Human genes 0.000 title 1
- 230000001177 retroviral effect Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 3
- 102000000588 Interleukin-2 Human genes 0.000 abstract 2
- 108010002350 Interleukin-2 Proteins 0.000 abstract 2
- 239000003443 antiviral agent Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000001415 gene therapy Methods 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 238000002716 delivery method Methods 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Un método de uso de genes integrasa negativos transdominantes para hacer al menos una célula resistente a infecciones retrovirales que incluyen infecciones retrovirales que resultan del VIH; un método de introducir un gene integrasa negativo transdominante en al menos una célula mamífera a dicha célula resistente a una infeccion retroviral así como vectores, células y métodos para construir las mismas utiles en los métodos antes citados; un método para tratar al SIDA que comprende la administracion a un paciente de una cantidad efectiva de un gen integrasa negativo transdominante solo o combinado con agentes utiles para la terapia de genes para la inhibicion de VIH, agentes antivirales o interlequina-2; y métodos de suministro farmacéutico que incluyen un gene integrasa negativo transdominante solo o combinado con agentes utiles para la terapia de genes de inhibicion de VIH, agentes antivirales o interleuquina-2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28657894A | 1994-08-05 | 1994-08-05 | |
| PCT/US1995/009110 WO1996004386A1 (en) | 1994-08-05 | 1995-07-19 | Method of using transdominant negative retroviral integrase in the treatment of retroviral infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9700560A true MX9700560A (es) | 1997-05-31 |
Family
ID=23099243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9700560A MX9700560A (es) | 1994-08-05 | 1995-07-19 | Metodo de uso de integrasa retroviral negativa transdominante en el tratamiento de infecciones retrovirales. |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US5908923A (es) |
| EP (1) | EP0774003A1 (es) |
| JP (1) | JPH10503654A (es) |
| CA (1) | CA2194488A1 (es) |
| MX (1) | MX9700560A (es) |
| WO (1) | WO1996004386A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9700560A (es) * | 1994-08-05 | 1997-05-31 | Warner Lambert Co | Metodo de uso de integrasa retroviral negativa transdominante en el tratamiento de infecciones retrovirales. |
| EP0893507A1 (en) | 1997-07-25 | 1999-01-27 | Institut Gustave Roussy | Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment |
| NZ503334A (en) * | 1997-09-15 | 2002-05-31 | Genetic Immunity Llc | A gene delivering complex having a vector with a specific affinity for a foreign genetic material and a second site having a specific affinity for a receptor on an antigen presenting cell |
| IT1297016B1 (it) * | 1997-12-23 | 1999-08-03 | San Raffaele Centro Fond | Processo di selezione di linfociti t cd4+ per la transduzione di geni anti-hiv |
| DE60044488D1 (de) | 1999-06-04 | 2010-07-15 | Nippon Inst For Biolog Science | Plasmidvektor |
| AU2020315598B2 (en) | 2019-07-16 | 2024-12-12 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
| CA3202466A1 (en) | 2021-01-14 | 2022-07-21 | Jiani LI | Hiv vaccines and methods of using |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6001810A (en) * | 1989-11-20 | 1999-12-14 | Eli Lilly And Company | Methods for treating retroviral infection |
| AU651380B2 (en) * | 1990-07-16 | 1994-07-21 | University Of Medicine And Dentistry Of New Jersey | Selection of ribozymes that efficiently cleave target RNA |
| WO1992003578A1 (en) * | 1990-08-24 | 1992-03-05 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | In vitro retroviral integration assay |
| US5217889A (en) * | 1990-10-19 | 1993-06-08 | Roninson Igor B | Methods and applications for efficient genetic suppressor elements |
| US5512421A (en) * | 1991-02-19 | 1996-04-30 | The Regents Of The University Of California | Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors |
| MX9700560A (es) * | 1994-08-05 | 1997-05-31 | Warner Lambert Co | Metodo de uso de integrasa retroviral negativa transdominante en el tratamiento de infecciones retrovirales. |
| US5993972A (en) * | 1996-08-26 | 1999-11-30 | Tyndale Plains-Hunter, Ltd. | Hydrophilic and hydrophobic polyether polyurethanes and uses therefor |
-
1995
- 1995-07-19 MX MX9700560A patent/MX9700560A/es not_active IP Right Cessation
- 1995-07-19 CA CA002194488A patent/CA2194488A1/en not_active Abandoned
- 1995-07-19 JP JP8506549A patent/JPH10503654A/ja not_active Abandoned
- 1995-07-19 WO PCT/US1995/009110 patent/WO1996004386A1/en not_active Ceased
- 1995-07-19 EP EP95927286A patent/EP0774003A1/en not_active Withdrawn
-
1997
- 1997-04-29 US US08/841,179 patent/US5908923A/en not_active Expired - Fee Related
-
1999
- 1999-01-14 US US09/231,182 patent/US6303334B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US5908923A (en) | 1999-06-01 |
| CA2194488A1 (en) | 1996-02-15 |
| WO1996004386A1 (en) | 1996-02-15 |
| JPH10503654A (ja) | 1998-04-07 |
| US6303334B1 (en) | 2001-10-16 |
| EP0774003A1 (en) | 1997-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1017797A4 (en) | NON-PRIMATE LENTIVIRAL VECTORS AND PACKING SYSTEMS | |
| AU690336B2 (en) | Genetic therapy of diseases caused by the immune system, said therapy using a cell-specific active substance regulated by the cell cycle | |
| DE69030880D1 (de) | Zusammensetzung zur Stimulierung des Immunsystems | |
| DK0703786T3 (da) | Anvendelse af nona- og dekapeptider til fremstilling af et lægemiddel til behandling af AIDS | |
| FI955509A0 (fi) | HIV-tartunnan ja AIDSin ribotsyymigeeniterapia | |
| ATE138384T1 (de) | Olionukleotidalkylphosphonate und - phosphonothioate | |
| ITMI922699A1 (it) | Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione | |
| HU9201258D0 (en) | Process for the production of medical preparations for treating hiv infections and of their active agents | |
| CA2395493A1 (en) | Hyaluronic acid in the treatment of cancer | |
| SE9101815D0 (sv) | Behandling av sjukdom foerbunden med hiv-infektioner | |
| MY134778A (en) | Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization | |
| ZA937147B (en) | Heterocyclic amines useful in the therapy of the asthma and of the inflammation of the respiratory tract | |
| YU47702A (sh) | Lečenje virusnih infekcija korišćenjem levovirina | |
| ZA968783B (en) | Flupirtine usage | |
| MY105855A (en) | Therapeutic nucleotides. | |
| NZ324157A (en) | Conditionally replicating viral vectors and their use in treating HIV | |
| NZ512850A (en) | Treatment of papillomavirus infections | |
| GR3033698T3 (en) | Use of a hymenoptera venom for the manufacture of a medicament for treating dna virus infections. | |
| GEP20012489B (en) | Use of Natural Human α-Interferon | |
| DE50009932D1 (de) | Gentransfer in humane lymphocyten mittels retroviraler scfv-zelltargeting vektoren | |
| MD1119G2 (ro) | Metodă de tratament al afecţiunilor inflamatorii ale organelor genitale feminine | |
| AU2396900A (en) | Treatment and prevention of hiv and other viral infections | |
| FR2427822A1 (fr) | Medicament pour le traitement des maladies circulatoires, a base de 5-methyl-7-dimethylamino-s-triazolo (1,5-a) pyrimidine | |
| NZ334634A (en) | Use of a protein extracted from mammalian liver for treating HIV | |
| ATE153533T1 (de) | Zubereitungen, die acyclovir-ähnliche verbindungen und 2'-vinylsubstituierte nukleosidanaloge enthalten, zur behandlung viraler infektionen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| MM | Annulment or lapse due to non-payment of fees |